Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
AL amyloidosis
AL amyloidosis
AL amyloidosis
Synonyms: Light-chain amyloidosis
Synonyms: Light-chain amyloidosis
Synonyms: Light-chain amyloidosis
Drug discovery
26
drugs
With orphan designations
Rare systemic or rheumatologic diseases
AL amyloidosis
Overview
AL amyloidosis is a systemic disorder caused by misfolded immunoglobulin light chains produced by clonal plasma cells, leading to progressive organ dysfunction. Cardiac and renal involvement are most common, with advanced cardiac disease conferring high mortality. Diagnosis relies on monoclonal protein detection, tissue biopsy with Congo red staining, and mass spectrometry. Treatment targets plasma cell clones to suppress toxic light chain production, combined with organ-supportive care [1][4][6][10].
Categories: rare cardiac diseases, rare hematological diseases, rare neoplastic diseases, rare neurological diseases, rare renal diseases, rare systemic and rheumatological diseases, rare transplant-related disorders
Research Papers
1,634 drug discovery papers about AL amyloidosis, with 2 first-in-class and 25 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
1,634 drug discovery papers about AL amyloidosis, with 2 first-in-class and 25 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-27 | Efficacy and Safety of ACEi, ARB, and ARNi in Cardiac Amyloidosis: A Retrospective Propensity Score-Matched Cohort Study.
Angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), and angiotensin receptor-neprilysin inhibitor (ARNi) improve outcomes in non-amyloid heart failure populations; however, their role in cardiac amyloidosis (CA) remains uncertain. We conducted a retrospective cohort study using the TriNetX Research Network including patients with CA. Patients receiving ACEi/ARB/ARNi were compared with those not receiving these therapies. Propensity score matching (1:1) was performed. Outcomes included all-cause mortality, hypotension, acute kidney injury (AKI), hyperkalemia, dizziness, and hospitalization over 3 years. Subgroup analyses were performed by sex, left ventricular ejection fraction (LVEF ≤40% vs >40%), and amyloidosis subtype. Among 5,134 patients, 1,692 (33.0%) received ACEi/ARB/ARNi. After matching, 1,447 patients remained in each group. Treatment was associated with lower all-cause mortality (HR, 0.64; p<0.001) but higher hospitalization (HR, 1.32; p<0.001). Risks of hypotension were similar, whereas AKI, hyperkalemia, and dizziness were higher with treatment. Findings were consistent across sex. Mortality reduction persisted in patients with LVEF >40% (HR 0.63, p < 0.001) and showed a similar non-significant trend in those with LVEF ≤40% (HR 0.58, p=0.058). A survival benefit was observed in AL amyloidosis (HR, 0.57; p <0.001) but not in ATTR amyloidosis (HR, 0.78; p=0.122). In selected patients with AL CA, treatment with ACEi/ARB/ARNi is associated with lower mortality; this association was not observed in patients with ATTR amyloidosis. Therapy was associated with a higher risk of side effects and hospitalizations. Randomized trials are needed to clarify the role of RAAS inhibition in CA.
2026-09-24 | Amyloid Light Chain Amyloidosis Involving the Heart and Temporal Arteries, Mimicking Giant Cell Arteritis.
Amyloid light chain (AL) amyloidosis is an uncommon multisystem condition. We report a globally unique case of a patient with AL amyloidosis affecting the heart and temporal arteries. A 74-year-old man presented with jaw claudication and temporal artery tenderness and was treated for giant cell arteritis. He was later admitted to the cardiology service with elevated cardiac biomarkers with echocardiographic features of an infiltrative cardiomyopathy. Cardiac magnetic resonance suggested amyloidosis, and diagnosis of AL amyloidosis was confirmed via temporal artery biopsy. Treatment with bortezomib, cyclophosphamide, and dexamethasone yielded an appropriate clinical response. Although AL amyloidosis is known to be associated with cardiac involvement with isolated cases of large vessel involvement, this is the first global case to our knowledge of AL amyloid affecting the temporal arteries and cardiac function simultaneously. AL amyloidosis is a multisystem disorder. Cardiac phenotyping should be mandatory.
2026-09-24 | Light Chain Cardiac Amyloidosis With Skeletal Muscle Weakness.
Amyloid light chain (AL) amyloidosis can manifest with heterogeneous, multisystem features. Cardiac involvement is common and drives prognosis. A 54-year-old man presented with proximal muscle weakness, autonomic and gastrointestinal symptoms, and exertional intolerance. Skeletal muscle imaging suggested myositis. Cardiac evaluation revealed conduction disease, and echocardiography was consistent with infiltrative cardiomyopathy. Fluorodeoxyglucose positron emission tomography demonstrated myocardial uptake. Targeted biopsies confirmed AL amyloidosis. Plasma cell-directed therapy achieved a partial hematologic response. Given the t(11;14), the patient began a trial of a novel BCL-2 inhibitor. Fluorodeoxyglucose-avid myocardium is described in amyloidosis but is not diagnostic. When a concurrent plasma cell clone or other red flags are present, a high index of suspicion should be maintained for AL amyloidosis. A high index of suspicion should be maintained for cardiac AL amyloidosis in patients with atypical cardiac findings. Unexplained muscle weakness should prompt evaluation for systemic AL amyloidosis even with subtle cardiac findings.
2026-09-24 | Early Recovery of Cardiac Function After Hematologic Response in Systemic AL Amyloidosis.
Cardiac involvement determines prognosis in systemic AL amyloidosis, and functional cardiac recovery typically lags hematologic response by months to years. A 40-year-old woman with biopsy-proven systemic AL amyloidosis and cardiac, renal, and hepatic involvement received cyclophosphamide, bortezomib, and dexamethasone, achieving rapid deep hematologic response, later consistent with complete response. Left ventricular ejection fraction improved from 40% to 58% and global longitudinal strain (GLS) from -9.2% to -12.1% within 4 months. At 1 year, GLS was -15.8%, and N-terminal pro B-type natriuretic peptide (NT-proBNP) fell from 2,397 pg/mL to 65 pg/mL, with hepatic and renal responses. Cardiac recovery in AL amyloidosis is usually delayed. The rapid improvement in left ventricular ejection fraction, GLS, and NT-proBNP in this case suggests relief from light chain-mediated injury with possible evolving amyloid regression. Early cardiac functional recovery may accompany deep hematologic response in AL amyloidosis. Serial echocardiography, including GLS, complements NT-proBNP in tracking cardiac response beyond hematologic remission alone.
2026-09-23 | Comparative Effectiveness of TTR Stabilizers for the Treatment of ATTR-CM Using Real-World Evidence.
Progression of transthyretin amyloid cardiomyopathy (ATTR-CM) can cause worsening congestion, requiring diuretic intensification (DI), heart failure (HF)-related hospitalizations (HFH), and death. Acoramidis and tafamidis are approved for ATTR-CM, but head-to-head trials are lacking. We evaluated the real-world comparative effectiveness of acoramidis versus tafamidis in newly treated patients with ATTR-CM. Retrospective study using Komodo Healthcare Map® US claims data tokenized to Claritas. Patients aged ≥18 years newly initiating acoramidis or tafamidis between 12/11/2024 and 04/30/2025 with ≥1 prescription claim (first defined as index date), ≥6 months continuous enrollment preindex date, no multiple myeloma, light chain amyloidosis, or hematopoietic stem cell treatments, and no prior treatments for ATTR-CM were included and followed until disenrollment, death, treatment switch, or study end (07/31/2025). Outcomes included DI (initiation or dose-equivalent escalation of oral loop diuretics, parenteral loop diuretic use, or addition of thiazide-like diuretic) and composite of DI, HFH (inpatient admission with HF-related International Classification of Diseases, 10th Revision, Clinical Modification, diagnosis code in any position), and mortality. Propensity score weighting balanced baseline characteristics, disease severity, comorbidity burden, and baseline medication use. Time-to-event outcomes were assessed using weighted Cox proportional hazards models. After weighting, patients treated with acoramidis (n = 170) and tafamidis (weighted sample size = 448) were comparable. Mean follow-up was 139 and 143 days, respectively. DI cumulative incidence curves separated early and remained divergent. Acoramidis significantly reduced the hazard of DI events by 43% versus tafamidis (11.8% vs. 20.5%; hazard ratio [HR], 0.57; 95% CI, 0.35-0.92; p = 0.021). Acoramidis had a significantly lower risk of composite events, with a 34% hazard reduction compared with tafamidis (17.6% vs. 26.4%; HR, 0.66; 95% CI, 0.44-0.99; p = 0.046). In this first real-world comparative effectiveness study of newly treated patients, acoramidis had a significantly lower risk of DI events and composite events of DI, HFH, and mortality than tafamidis, potentially supporting improved clinical stability with acoramidis initiation. Additional evaluation with longer follow-up, larger cohorts, and/or prospective clinical outcomes is warranted. Graphical abstract available for this article.
proteins
2026-06-29 | Siphoviridae phage tails co-enrich with ex vivo amyloids.
Bacteriophages are ubiquitous in the environment and are part of the natural human microbiome. Despite their abundance, the role of the human phagome in health and disease remains poorly understood. Here, we identify phage tails in ex vivo amyloid extracts from patients with lysozyme amyloidosis (ALys) and light-chain amyloidosis (AL). Using cryo-EM analysis of the ALys dataset, automated model building, and database searches, we assigned the observed tubular assemblies to a phage tail tube protein (TTP). Although we cannot fully rule out the possibility of contamination, the presence of phage tails raises the question of whether they bind to and are co-purified with amyloid fibrils. These structures may provide further insight into the potential relationship between phage-derived assemblies and amyloid remodeling, with possible implications for future therapeutic strategies in human amyloidosis.
2026-06-22 | Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.
Light chain (LC) amyloidosis (AL) is a fatal disorder caused by extracellular aggregation of monoclonal immunoglobulin LCs. While both λ and κ isotypes can be involved, κ-LCs account for only ∼20% of cases, and their aggregation mechanisms remain less understood. Recent evidence suggests that N-glycosylation influences κ-LC aggregation and is strongly linked to AL amyloidosis. To investigate this, we examined patient-derived κ-LCs in both glycosylated and unglycosylated forms. Mass spectrometry confirmed the presence of complex-type N-glycans. Biophysical analyses showed that glycosylation enhances structural compactness, stabilizes the native structure, and promotes cooperative unfolding. Glycosylated κ-LCs also exhibited reduced conformational dynamics. Functionally, N-glycosylation significantly improved LC secretion efficiency and extracellular stability. These findings suggest that N-glycosylation acts as a protective factor against amyloid formation and enhances LC accumulation outside the cell. Overall, our study highlights the multifaceted and context-dependent role of N-glycosylation in modulating κ-LC behavior, with important implications in AL pathogenesis.
2026-05-21 | A CDR1 aggregation hotspot controls unfolding kinetics and multimolecular aggregation in IGLV2 light chains.
Immunoglobulin light chains (LCs) exhibit diverse aggregation behaviours that depend sensitively on sequence composition and intermolecular interactions. Understanding how specific residues modulate aggregation kinetics remains a key challenge in elucidating the molecular basis of light-chain amyloidosis. Here, we investigate sequence-dependent aggregation using recombinant λ LCs derived from the IGLV2 gene family. Comparison of two closely related LCs differing by only 16 amino acids revealed striking differences in aggregation behaviour under thermal stress. Bioinformatic analysis identified an additional aggregation-prone segment in the CDR1 region of the aggregation-prone M10 variant, associated with residues Ser33 and Tyr34. Rational substitution of these residues (S33D/Y34S) markedly reduced aggregation while leaving the thermal transition temperature largely unchanged (∼53 °C). Differential scanning calorimetry revealed that the wild-type M10 LC unfolds with a significantly lower apparent activation energy (∼290 kJ/mol) compared with the non-aggregating H9 (∼605 kJ/mol) and the stabilised double mutant (∼560 kJ/mol), indicating reduced kinetic stability. Aggregation of unfolded species showed much weaker temperature dependence (Ea ≈ 10-70 kJ/mol) and exhibited strong concentration dependence consistent with a multimolecular association process. Additional experiments suggest that aromatic interactions involving Tyr34 contribute to the stabilisation of intermolecular assemblies. Together, these results establish a quantitative link between local sequence variation in the CDR1 region, kinetic stability of the LC fold, and aggregation propensity, highlighting how targeted mutations can modulate aggregation behaviour in immunoglobulin light chains.
2026-04-08 | Preventing Pathogenic Dimerization in a Misfolded Antibody Light Chain through the Design of an Inhibitory Peptide.
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. The disease correlates with the formation of insoluble aggregates mostly composed of patient-specific antibody light chains, whose hypervariable regions make each case unique and highlight the need for personalized therapeutics. In this study, we focused on a pathogenic homodimer we previously obtained from a patient-derived light chain. By analyzing the dynamics and the interface of this dimer, we identified a peptide with potential inhibitory activity. The peptide was then refined using a computational mutagenesis protocol that iteratively improved its sequence to maximize complementarity with the protein interface, taking into account shape, electrostatics, and hydropathy. The resulting optimized peptide is found to bind the monomer with a binding affinity comparable to that of the full pathogenic interface. These results suggest that the designed peptide could act as an effective antagonist of the pathogenic dimer, and demonstrate that our computational strategy could provide a general framework for designing patient-specific inhibitory peptides against aggregation-prone proteins.
2025-06-02 | The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies.
BackgroundAnti-CD38 directed therapies have emerged as targeted treatments for multiple myeloma (MM) and light chain (AL) amyloidosis. Intravenous immunoglobulin (IVIG) supplementation has been shown to reduce the risk of bacterial infections by 39% in patients with MM receiving anti-CD38 therapies, with a 72% reduction in grade 3-4 infections. However, there is currently no universal guidance on the optimal population in whom to initiate IVIG prophylaxis to prevent these infectious complications.MethodsThis study was a retrospective, single-centered chart review of eligible patients treated at Yale New Haven Health System (YNHHS) from 2016-2022. Eligible patients included adults with MM or AL amyloidosis treated with an anti-CD38 based regimen. The primary outcome was to compare the rate of pneumonia in patients who have received IVIG as compared to patients who have not. The secondary outcome was to identify the immunoglobulin G (IgG) level associated with an increased risk of pneumonia.ResultsRates of pneumonia were found to be higher within the population receiving IVIG as compared to those not receiving IVIG (29.55% vs. 15.41%, p = 0.05). There were no significant differences in the subgroup analyses including line of therapy, anti-CD38 agent, diagnosis, and IgG disease involvement. There was also no significant correlation demonstrated between baseline IgG level and the occurrence of pneumonia (β1 -0.0001, p = 0.37).ConclusionsIVIG supplementation in patients receiving anti-CD38 directed therapy did not significantly reduce the incidence of pneumonia. Given the lack of benefit with IVIG supplementation, careful consideration must be given prior to administration to limit unnecessary utilization.
cell therapies
2026-07-21 | Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis.
B-cell maturation antigen (BCMA)-targeted therapies have emerged as promising treatment options for patients with relapsed/refractory immunoglobulin light-chain (AL) amyloidosis. However, comprehensive data on their efficacy and safety remain limited. We conducted a systematic descriptive pooled analysis of published studies reporting outcomes of BCMA-directed therapies including chimeric antigen receptor T-cell (CAR-T) therapies, bispecific antibodies (BsAbs), and antibody-drug conjugate (ADC). The analysis included 256 patients. CAR-T therapy was administered to 89 patients (35%), BsAbs to 82 patients (32%), and ADCs to 85 patients (33%). The pooled overall response rate (ORR) was 83%, with CAR-T demonstrating 92% ORR, BsAbs 89%, and ADCs 68%. Deep hematologic responses (≥VGPR) were achieved in approximately 70% of CAR-T and BsAb recipients and 64% of ADC recipients. Minimal residual disease negativity was documented in 75% of evaluable CAR-T patients and in 86% evaluable BsAb patients with reported data. Organ responses were observed in 30% of evaluable patients, with cardiac responses in 41%. Cytokine release syndrome occurred in 74% of CAR-T and 49% of BsAb patients, predominantly grade 1-2. Grade ≥3 CRS was rare (9% CAR-T, 1% BsAb). Ocular toxicity was the predominant adverse event in ADC recipients (84% any grade, 29% grade ≥3). Grade ≥3 infections occurred in 13% of CAR-T, 20% of BsAb, and 6% of ADC patients. BCMA-targeted therapies result in high response rates with manageable safety profiles in heavily pretreated AL amyloidosis patients, supporting continued investigation and clinical application of these approaches.
2026-06-23 | Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.
The role of autologous stem cell transplantation (ASCT) is central in AL amyloidosis and continues to be defined in the era of newer therapies. To evaluate contemporary patient selection, practice patterns, and outcomes, we conducted a retrospective, multicenter study across nine tertiary referral centers, including 1047 patients with AL amyloidosis who underwent ASCT between 2010 and 2020. Most patients (67.9%) received full-dose melphalan conditioning, and 66.5% received pre-ASCT induction therapy, predominantly proteasome inhibitor-based regimens. Day-100 all-cause mortality was 3.0%, representing a substantial improvement compared with historical cohorts. Post-ASCT hematological responses were satisfactory in 75.4% of patients. Among patients with paired assessments, ASCT deepened responses in 56.3% who had not achieved a complete response with induction therapy. With a median follow-up of 5.1 years, the median overall survival was 6.3 years. Independent predictors of inferior survival included age ≥60 years, bone marrow plasma cells ≥20%, pre-ASCT dFLC ≥40 mg/L, elevated cardiac biomarkers, lambda-restricted disease, reduced eGFR and reduced-dose conditioning. In this contemporary cohort, ASCT for AL amyloidosis demonstrated low early mortality, high rates of deep hematologic response, and durable survival in carefully selected patients. These findings support its role as an effective consolidative strategy, while its optimal positioning alongside emerging therapies requires further study.
2026-05-01 | A rare case of renal AHL amyloidosis with marked complement deposition: clinicopathologic and proteomic findings.
Amyloidosis comprises a heterogeneous group of diseases characterized by extracellular deposition of β-pleated-sheet fibrillar proteins that cause progressive organ dysfunction. Among immunoglobulin-related amyloidosis, combined heavy- and light-chain (AHL) amyloidosis is extremely rare, which accounts for approximately 7%. Several studies have demonstrated that complement components can be detected in renal amyloidosis. We report a rare case of renal AHL amyloidosis with marked complement deposition with clinicopathologic and proteomic insights. A 76-year-old woman with a five-year history of microscopic hematuria developed mild renal dysfunction (serum creatinine 1.05 mg/dL) and proteinuria (0.95 g/day). Physical and serologic evaluations showed no evidence of systemic amyloidosis or autoimmune disease. Serum and urine immunofixation detected an IgG-κ M-protein, and bone marrow findings were consistent with monoclonal gammopathy of undetermined significance. Kidney biopsy demonstrated Congo red-positive fibrillar deposits with IgG1, κ, and complement (C3/C1q) staining. Electron microscopy revealed non-branching fibrils measuring 8 to 12 nm in diameter. Because marked complement deposition was observed, fibrillary glomerulonephritis (FGN) was considered in the differential diagnosis. However, negative Dna J heat-shock protein family B member 9 immunostaining raised suspicion for amyloidosis. Mass spectrometry identified IgG1 heavy and κ light chains together with serum amyloid P and apolipoprotein E, confirming IgG1-κ-type AHL amyloidosis. This case illustrates a presentation of AHL amyloidosis with marked complement deposition. Recent study reveals that complement components can be detected in a subset of amyloidosis cases. These features can complicate the differential diagnosis from FGN and highlight the importance of an integrated diagnostic approach combining histopathology, immunostaining, and proteomic analysis. Furthermore, clone-directed therapy targeting the pathogenic plasma cell clone may represent a rational therapeutic strategy for monoclonal immunoglobulin-associated renal disease.
2026-02-05 | Improvement in Cardiac Magnetic Resonance Parameters in Patients With Cardiac Light-Chain Amyloidosis Receiving Anticlonal Cell Therapy.
We sought to evaluate the pattern of changes in cardiac magnetic resonance parameters among light-chain (AL) cardiac amyloidosis patients receiving anticlonal therapy. This study included 35 consecutive patients with AL cardiac amyloidosis (AL CA) from a single amyloidosis center, surviving at least 1 year after diagnosis and undergoing 3T CMR at diagnosis and at 12-months follow-up. Structural, functional parameters, native T1, T2, myocardial and spleen extracellular volume (ECV), and peak left atrial strain (PALS) were recorded. Hematologic response was assessed per current criteria. Mean age was 64.1 years, 57% males and per Mayo staging system 10% were stage I, 32% stage II, and 58% stage III. During follow-up, 54.3% achieved complete hematologic response (CR), 34.3% very good partial response, and 11.4% partial response. Significant changes at 12-month landmark included a reduction in native T1 (1420 ms vs. 1393 ms, P = .001), ECV (46% vs. 43%, P = .004), left ventricular maximum wall thickness (15 mm vs. 13 mm, P = .02), and an increase in stroke volume (76 mL vs. 85 mL, P = .016). Patients with complete hematologic or cardiac response demonstrated improvements in T1 native and ECV. In a subset of n = 12 patients with a repeated follow-up CMR study at a median of 31.2 ± 5.04 months after treatment initiation, a trend towards further reduction in T1 and ECV was noted. In AL-CA patients treated with anticlonal therapy, significant improvement in CMR parameters, correlate with hematologic and organ response and suggest potential cardiac amyloid regression and functional improvement.
2025-12-08 | Up-to-date review on heart transplantation and other advanced heart failure therapies in cardiac amyloidosis patients.
Cardiac amyloidosis (CA) can result in a restrictive cardiomyopathy, and heart transplantation (HT) remains the gold standard treatment for patients with end-stage heart failure secondary to amyloid cardiomyopathy. Although HT was historically contraindicated due to inferior outcomes, survival following HT in patients with CA has significantly improved over recent decades; and outcomes are now similar to those of patients undergoing HT for non-amyloid indications. This improvement has been driven largely by advances in screening for appropriate patient selection and improvement in therapeutic strategies for both immunoglobulin light-chain (AL) and transthyretin (ATTR) amyloidosis. Future directions in HT for CA will hinge on continued optimization of patient selection and refining post-transplant management of extracardiac manifestations.
antibodies
2026-09-13 | 294th ENMC international workshop: Diagnosis and management of paraproteinemic myopathies focusing on sporadic late-onset nemaline myopathy (SLONM) and light-chain (AL) amyloid myopathy. 27th -29th March 2026, Hoofddorp, The Netherlands.
Paraproteinemic myopathies are rare but potentially treatable disorders caused by pathogenic monoclonal proteins, yet diagnosis is often delayed because of nonspecific clinical manifestations and the lack of standardized diagnostic approaches. The 294th ENMC International Workshop convened 21 experts from 12 countries and two patient representatives to establish international consensus on their diagnosis and management. The workshop reviewed current evidence on sporadic late-onset nemaline myopathy (SLONM), light-chain (AL) amyloid myopathy, vacuolar myopathy with monoclonal gammopathy and stiffness (VAMMGAS), and scleromyxedema-associated myopathy. Clinical red flags include age at symptom onset ≥40 years, subacute proximal and/or axial weakness, normal or mildly elevated creatine kinase levels (except in VAMMGAS), dysphagia, weight loss, systemic manifestations, and poor response to conventional immunotherapy. Consensus diagnostic criteria for SLONM and a diagnostic algorithm for paraproteinemic myopathies were established. Routine Congo red staining of muscle biopsies, particularly in patients with monoclonal protein, was recommended. The workshop endorsed replacing SLONM-MGUS with SLONM-MP to reflect the pathogenic role of the monoclonal protein and recommended plasma cell-directed therapy as the cornerstone of treatment for SLONM-MP and AL amyloid myopathy. These recommendations provide the first international consensus framework for the diagnosis and management of paraproteinemic myopathies and establish priorities for future collaborative research.
2026-08-28 | 9-Year Serial CMR Monitoring of Cardiac AL Amyloidosis Regression After Teclistamab.
Cardiac amyloid light-chain (AL) amyloidosis carries a poor prognosis and is considered largely irreversible once symptomatic. Long-term serial cardiovascular magnetic resonance (CMR) data following B-cell maturation antigen-directed therapy are lacking. A 64-year-old man with biopsy-proven cardiac AL amyloidosis achieved sustained hematologic complete response after teclistamab following failure of 4 prior lines including daratumumab. Eleven CMR examinations over 9 years documented a biphasic trajectory: progressive infiltration through 2020 (left ventricular mass 186 g, wall thickness 18 mm, global longitudinal strain -4.8%), followed by sustained structural and functional regression through 2025 (left ventricular mass 127 g, wall thickness 13 mm, global longitudinal strain -13.7%). This represents the longest serial CMR follow-up in cardiac AL amyloidosis reported to date, demonstrating that cine-derived parameters reliably track cardiac regression in real-world conditions. Native T1 normalized while extracellular volume fraction (ECV) paradoxically increased, suggesting persistent fibril burden beyond hematologic clearance. Serial CMR with cine-derived parameters provides robust longitudinal monitoring of cardiac AL amyloidosis regression following novel plasma cell-directed therapy, even without systematic contrast enhancement.
2026-08-10 | IgM Pleural Amyloidosis Diagnosed by Pleural Effusion Cell Block: A Case Report.
Immunoglobulin light chain (AL) amyloidosis is characterized by the systemic deposition of light-chain-derived amyloids. Immunoglobulin M (IgM)-associated AL amyloidosis is extremely rare and clinically distinct. A 70-year-old man presented with dyspnea, bilateral pleural effusion, and mediastinal lymphadenopathy on computed tomography (CT). Amyloid was detected in a pleural effusion cell block and confirmed via an axillary lymph node biopsy. Serum studies and bone marrow findings supported IgM-λ AL amyloidosis associated with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. First-line therapy failed, but second-line therapy reduced pleural effusion, avoiding thoracentesis for one year. A pleural effusion cell block analysis enabled rapid diagnosis with minimally invasive exploration.
2026-07-20 | Histopathological improvement in kidney AL amyloid deposits following daratumumab-based chemotherapy and autologous peripheral blood stem cell transplantation: a case report.
AL amyloidosis is characterized by extracellular deposition of immunoglobulin light-chain fibrils, frequently leading to kidney involvement and progressive organ dysfunction. We report a case of kidney AL amyloidosis secondary to multiple myeloma in which daratumumab-based chemotherapy combined with autologous peripheral blood stem cell transplantation resulted in marked improvement, as confirmed by sequential kidney biopsy. The initial biopsy revealed vascular-dominant amyloid deposition, whereas the second biopsy obtained 2 years later demonstrated a marked reduction in amyloid burden, particularly within the vascular compartments. This histopathological improvement corresponded with hematologic remission and stabilization of kidney function. The observed reduction in tissue amyloid deposits was presumed to result from suppression of amyloidogenic light chains, leading to inhibition of new fibril formation and subsequent tissue remodeling. Our findings provide direct pathological evidence that daratumumab-based combination therapy, through immune-mediated plasma cell depletion, may indirectly promote the regression of amyloid deposits and contribute to functional recovery.
2026-07-09 | Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions.
Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific discoveries regarding the molecular mechanisms of transthyretin misfolding and aggregation have driven the development of drugs for the treatment of transthyretin (ATTR) amyloidosis, with six novel therapies approved since 2018. The combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone was approved for the treatment of light chain (AL) amyloidosis in 2021. Since then, highly effective immunotherapies, such as bispecific T-cell engagers, have been tested in clinical trials in patients with relapsed AL amyloidosis, with unprecedented efficacy. Thus, suspicion of systemic amyloidosis should be raised early in individuals with a suggestive clinical presentation, followed by rapid tissue diagnosis, with appropriate protein typing and prompt commencement of active therapy. These rapid and exciting therapeutic advancements set the stage for this Review on the epidemiology, pathophysiology, and diagnosis of systemic amyloidosis. Through the lens of the molecular mechanisms underlying amyloidosis pathogenesis, we will focus on approved and investigational therapies. We also discuss future directions and challenges concerning a cure for patients with AL or ATTR amyloidosis.
other
2025-09-27 | What Cardiologists Should Know About Amyloidosis.
Background: Cardiac amyloidosis (CA) is an increasingly recognized but historically underdiagnosed cause of restrictive cardiomyopathy and heart failure with preserved ejection fraction (HFpEF). It results from the extracellular deposition of misfolded protein fibrils, most commonly transthyretin (ATTR) or immunoglobulin light chains (AL), leading to progressive myocardial dysfunction and multi-organ involvement. Objective: This review provides a comprehensive, cardiology-centered overview of cardiac amyloidosis, with an emphasis on early recognition, diagnostic strategies, subtype differentiation, and the evolving therapies. Content: We summarize the epidemiology, pathophysiology, and clinical manifestations of both ATTR and AL subtypes. Key diagnostic tools, including echocardiography, cardiac magnetic resonance imaging, bone scintigraphy, monoclonal protein screening, and endomyocardial biopsy, are reviewed in the context of a stepwise diagnostic approach. Special attention is given to clinical presentation, electrocardiographic and imaging "red flags," and to differentiating CA from mimickers such as hypertrophic cardiomyopathy, hypertension-induced left ventricular hypertrophy, and aortic stenosis. Staging systems are detailed, highlighting the prognostic role of cardiac biomarkers. Therapeutic strategies are explored, including subtype-specific regimens (e.g., daratumumab-based therapy for AL; tafamidis and gene silencers for ATTR), the judicious use of conventional heart failure medications, and emerging therapies such as CRISPR-based gene editing. Conclusions: Timely recognition and accurate diagnosis of cardiac amyloidosis are critical to improving outcomes. As diagnostic tools and disease-modifying therapies evolve rapidly, cardiologists must remain at the forefront of multidisciplinary care. A structured biomarker- and imaging-guided approach can enhance diagnostic yield, inform prognosis, and optimize patient-specific management.
2025-09-26 | Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin (TTR) in peripheral nerves. Nexiguran ziclumeran (nex-z) is an investigational in vivo therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) that is designed to reduce serum TTR levels through selective inactivation of TTR in the liver. In this phase 1, open-label study, we administered one infusion of nex-z to patients with ATTRv-PN. Primary objectives included assessment of the safety and pharmacodynamics of nex-z. Secondary end points included changes in the familial amyloid polyneuropathy stage, polyneuropathy disability score, serum neurofilament light chain (NfL) level, modified body-mass index (modified BMI, defined as the conventional BMI [weight in kilograms divided by square of height in meters] multiplied by the albumin level in grams per liter), and modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment). A total of 36 patients received nex-z; the mean follow-up was 27 months. The mean percent change from baseline in the serum TTR level was -90% at day 28, which was sustained through month 24 (-92%). Treatment-related adverse events included transient infusion-related reactions (in 21 patients), decreased thyroxine level without hypothyroidism or elevated thyrotropin level (in 8), and headache (in 4). One participant died from cardiac amyloidosis, and one withdrew owing to progressive decline in motor function. Serious adverse events were reported in 11 patients. At month 24, the familial amyloid polyneuropathy stage and polyneuropathy disability score remained stable in 29 and 27 patients, respectively; improved in 2 and 5, respectively; and worsened in 2 and 2, respectively. The mean change in the serum NfL level was -9.0 pg per milliliter, and the change in the modified BMI was 24.7. The mean change from baseline in the mNIS+7 was -8.5. A single administration of nex-z in patients with ATTRv-PN was associated with rapid, deep, and durable reductions in serum TTR levels. The results support further investigation of nex-z to treat ATTRv-PN. (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
2025-05-28 | Cardiac Amyloidosis: A Narrative Review of Diagnostic Advances and Emerging Therapies.
Background/Objectives: Cardiac amyloidosis (CA) is an underdiagnosed and potentially life-threatening infiltrative cardiomyopathy characterized by the extracellular deposition of misfolded amyloid fibrils in cardiac tissue. It is most commonly associated with light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis, either hereditary or wild-type. The disease often presents with non-specific symptoms, leading to delayed diagnosis and treatment. This study aims to provide a comprehensive overview of the pathophysiology, diagnostic strategies, and current therapeutic approaches for cardiac amyloidosis, with a focus on improving early detection and clinical outcomes. Methods: A narrative review was conducted using databases such as PubMed and Scopus, covering the period from September 2016 to March 2025. Keywords such as "cardiac amyloidosis", "cardiac amyloidosis from transthyretin", "cardiomyopathy", "transthyretin", "immunoglobulin light-chain amyloidosis", and "familial amyloidosis" were used. Relevant clinical trials and guideline-based management recommendations were also included. Results: This review highlights that non-invasive imaging modalities and serum biomarker analyses are key to reducing diagnostic delays. New therapeutic developments, including gene-editing technologies and RNA-based therapies, show promise in early trials. Multidisciplinary management and increased awareness are crucial for timely diagnosis and treatment optimization. Conclusions: The early recognition of cardiac amyloidosis remains a major clinical challenge. Advances in non-invasive diagnostics and emerging disease-modifying therapies are transforming the prognosis of affected patients. Continued research and heightened clinical suspicion are essential to improve outcomes in this complex and heterogeneous disease.
2025-01-17 | New therapies to treat cardiac amyloidosis.
Review advancements in therapies for transthyretin (ATTR-CM) and immunoglobulin light chain (AL-CM) cardiac amyloidosis. In ATTR-CM, tafamidis remains the cornerstone therapy, with Food and Drug Administration (FDA) approval for over 5 years. Acoramidis, another transthyretin stabilizer, has very recently been FDA-approved following positive results in the ATTRibute-CM trial. Vutrisiran, a transthyretin gene silencer, demonstrated efficacy in the HELIOS-B trial and awaits FDA review. Eplontersen's CARDIO-TTRansform trial, the largest ATTR-CM study to date, is expected to report by late 2025. Innovative approaches such as NTLA-2001 (a CRISPR-Cas9 therapy) and fibril depleters like ALXN2220 and coramitug are advancing in clinical trials. In AL-CM, daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) has established itself as the standard of care. Novel antiplasma cell therapies include CAR-T cells and bispecific antibodies (teclistimab) and fibril depleters. Birtamimab improved survival in advanced AL-CM during the VITAL trial and is under investigation in AFFIRM-AL. Anselamimab is in phase III CARES trials, whereas AT-02 undergoes early-phase testing for ATTR-CM and AL-CM. The therapeutic landscape for ATTR-CM and AL-CM is rapidly evolving, driven by novel therapies targeting diverse mechanisms. Ongoing clinical trials promise to further refine the standard of care and improve outcomes for patients with cardiac amyloidosis.
2024-08-19 | Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment.
Cardiac amyloidosis (CA) is a condition characterized by misfolding and extracellular deposition of proteins, leading to organ dysfunction. While numerous forms of CA exist, two subtypes dominate clinical prevalence: Transthyretin amyloid (ATTR) and immunoglobulin light chain amyloid. The current scientific landscape reflects the urgency to advance therapeutic interventions with over 100 ongoing clinical trials. Heart failure treatment is affected by CA phenotype with poor tolerance of otherwise frequently used medications. Treating comorbidities including atrial fibrillation and valvular disease remains a challenge in CA, driven by technical difficulties and uncertain outcomes. Tafamidis is the first ATTR-stabilizer approved with a rapidly growing rate of clinical use. In parallel, various new therapeutic classes are in late-stage clinical trials including silencers, antibodies and genetic therapy. Managing CA is a critical challenge for future heart failure care. This review delineates the current standard-of-care and scientific landscape of CA therapy.
small molecules
2026-09-27 | Efficacy and Safety of ACEi, ARB, and ARNi in Cardiac Amyloidosis: A Retrospective Propensity Score-Matched Cohort Study.
Angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB), and angiotensin receptor-neprilysin inhibitor (ARNi) improve outcomes in non-amyloid heart failure populations; however, their role in cardiac amyloidosis (CA) remains uncertain. We conducted a retrospective cohort study using the TriNetX Research Network including patients with CA. Patients receiving ACEi/ARB/ARNi were compared with those not receiving these therapies. Propensity score matching (1:1) was performed. Outcomes included all-cause mortality, hypotension, acute kidney injury (AKI), hyperkalemia, dizziness, and hospitalization over 3 years. Subgroup analyses were performed by sex, left ventricular ejection fraction (LVEF ≤40% vs >40%), and amyloidosis subtype. Among 5,134 patients, 1,692 (33.0%) received ACEi/ARB/ARNi. After matching, 1,447 patients remained in each group. Treatment was associated with lower all-cause mortality (HR, 0.64; p<0.001) but higher hospitalization (HR, 1.32; p<0.001). Risks of hypotension were similar, whereas AKI, hyperkalemia, and dizziness were higher with treatment. Findings were consistent across sex. Mortality reduction persisted in patients with LVEF >40% (HR 0.63, p < 0.001) and showed a similar non-significant trend in those with LVEF ≤40% (HR 0.58, p=0.058). A survival benefit was observed in AL amyloidosis (HR, 0.57; p <0.001) but not in ATTR amyloidosis (HR, 0.78; p=0.122). In selected patients with AL CA, treatment with ACEi/ARB/ARNi is associated with lower mortality; this association was not observed in patients with ATTR amyloidosis. Therapy was associated with a higher risk of side effects and hospitalizations. Randomized trials are needed to clarify the role of RAAS inhibition in CA.
2026-09-24 | Amyloid Light Chain Amyloidosis Involving the Heart and Temporal Arteries, Mimicking Giant Cell Arteritis.
Amyloid light chain (AL) amyloidosis is an uncommon multisystem condition. We report a globally unique case of a patient with AL amyloidosis affecting the heart and temporal arteries. A 74-year-old man presented with jaw claudication and temporal artery tenderness and was treated for giant cell arteritis. He was later admitted to the cardiology service with elevated cardiac biomarkers with echocardiographic features of an infiltrative cardiomyopathy. Cardiac magnetic resonance suggested amyloidosis, and diagnosis of AL amyloidosis was confirmed via temporal artery biopsy. Treatment with bortezomib, cyclophosphamide, and dexamethasone yielded an appropriate clinical response. Although AL amyloidosis is known to be associated with cardiac involvement with isolated cases of large vessel involvement, this is the first global case to our knowledge of AL amyloid affecting the temporal arteries and cardiac function simultaneously. AL amyloidosis is a multisystem disorder. Cardiac phenotyping should be mandatory.
2026-09-24 | Light Chain Cardiac Amyloidosis With Skeletal Muscle Weakness.
Amyloid light chain (AL) amyloidosis can manifest with heterogeneous, multisystem features. Cardiac involvement is common and drives prognosis. A 54-year-old man presented with proximal muscle weakness, autonomic and gastrointestinal symptoms, and exertional intolerance. Skeletal muscle imaging suggested myositis. Cardiac evaluation revealed conduction disease, and echocardiography was consistent with infiltrative cardiomyopathy. Fluorodeoxyglucose positron emission tomography demonstrated myocardial uptake. Targeted biopsies confirmed AL amyloidosis. Plasma cell-directed therapy achieved a partial hematologic response. Given the t(11;14), the patient began a trial of a novel BCL-2 inhibitor. Fluorodeoxyglucose-avid myocardium is described in amyloidosis but is not diagnostic. When a concurrent plasma cell clone or other red flags are present, a high index of suspicion should be maintained for AL amyloidosis. A high index of suspicion should be maintained for cardiac AL amyloidosis in patients with atypical cardiac findings. Unexplained muscle weakness should prompt evaluation for systemic AL amyloidosis even with subtle cardiac findings.
2026-09-24 | Early Recovery of Cardiac Function After Hematologic Response in Systemic AL Amyloidosis.
Cardiac involvement determines prognosis in systemic AL amyloidosis, and functional cardiac recovery typically lags hematologic response by months to years. A 40-year-old woman with biopsy-proven systemic AL amyloidosis and cardiac, renal, and hepatic involvement received cyclophosphamide, bortezomib, and dexamethasone, achieving rapid deep hematologic response, later consistent with complete response. Left ventricular ejection fraction improved from 40% to 58% and global longitudinal strain (GLS) from -9.2% to -12.1% within 4 months. At 1 year, GLS was -15.8%, and N-terminal pro B-type natriuretic peptide (NT-proBNP) fell from 2,397 pg/mL to 65 pg/mL, with hepatic and renal responses. Cardiac recovery in AL amyloidosis is usually delayed. The rapid improvement in left ventricular ejection fraction, GLS, and NT-proBNP in this case suggests relief from light chain-mediated injury with possible evolving amyloid regression. Early cardiac functional recovery may accompany deep hematologic response in AL amyloidosis. Serial echocardiography, including GLS, complements NT-proBNP in tracking cardiac response beyond hematologic remission alone.
2026-09-23 | Comparative Effectiveness of TTR Stabilizers for the Treatment of ATTR-CM Using Real-World Evidence.
Progression of transthyretin amyloid cardiomyopathy (ATTR-CM) can cause worsening congestion, requiring diuretic intensification (DI), heart failure (HF)-related hospitalizations (HFH), and death. Acoramidis and tafamidis are approved for ATTR-CM, but head-to-head trials are lacking. We evaluated the real-world comparative effectiveness of acoramidis versus tafamidis in newly treated patients with ATTR-CM. Retrospective study using Komodo Healthcare Map® US claims data tokenized to Claritas. Patients aged ≥18 years newly initiating acoramidis or tafamidis between 12/11/2024 and 04/30/2025 with ≥1 prescription claim (first defined as index date), ≥6 months continuous enrollment preindex date, no multiple myeloma, light chain amyloidosis, or hematopoietic stem cell treatments, and no prior treatments for ATTR-CM were included and followed until disenrollment, death, treatment switch, or study end (07/31/2025). Outcomes included DI (initiation or dose-equivalent escalation of oral loop diuretics, parenteral loop diuretic use, or addition of thiazide-like diuretic) and composite of DI, HFH (inpatient admission with HF-related International Classification of Diseases, 10th Revision, Clinical Modification, diagnosis code in any position), and mortality. Propensity score weighting balanced baseline characteristics, disease severity, comorbidity burden, and baseline medication use. Time-to-event outcomes were assessed using weighted Cox proportional hazards models. After weighting, patients treated with acoramidis (n = 170) and tafamidis (weighted sample size = 448) were comparable. Mean follow-up was 139 and 143 days, respectively. DI cumulative incidence curves separated early and remained divergent. Acoramidis significantly reduced the hazard of DI events by 43% versus tafamidis (11.8% vs. 20.5%; hazard ratio [HR], 0.57; 95% CI, 0.35-0.92; p = 0.021). Acoramidis had a significantly lower risk of composite events, with a 34% hazard reduction compared with tafamidis (17.6% vs. 26.4%; HR, 0.66; 95% CI, 0.44-0.99; p = 0.046). In this first real-world comparative effectiveness study of newly treated patients, acoramidis had a significantly lower risk of DI events and composite events of DI, HFH, and mortality than tafamidis, potentially supporting improved clinical stability with acoramidis initiation. Additional evaluation with longer follow-up, larger cohorts, and/or prospective clinical outcomes is warranted. Graphical abstract available for this article.
proteins
2026-06-29 | Siphoviridae phage tails co-enrich with ex vivo amyloids.
Bacteriophages are ubiquitous in the environment and are part of the natural human microbiome. Despite their abundance, the role of the human phagome in health and disease remains poorly understood. Here, we identify phage tails in ex vivo amyloid extracts from patients with lysozyme amyloidosis (ALys) and light-chain amyloidosis (AL). Using cryo-EM analysis of the ALys dataset, automated model building, and database searches, we assigned the observed tubular assemblies to a phage tail tube protein (TTP). Although we cannot fully rule out the possibility of contamination, the presence of phage tails raises the question of whether they bind to and are co-purified with amyloid fibrils. These structures may provide further insight into the potential relationship between phage-derived assemblies and amyloid remodeling, with possible implications for future therapeutic strategies in human amyloidosis.
2026-06-22 | Multifaceted effects of N-glycosylation on amyloidogenic κ light chains in AL amyloidosis.
Light chain (LC) amyloidosis (AL) is a fatal disorder caused by extracellular aggregation of monoclonal immunoglobulin LCs. While both λ and κ isotypes can be involved, κ-LCs account for only ∼20% of cases, and their aggregation mechanisms remain less understood. Recent evidence suggests that N-glycosylation influences κ-LC aggregation and is strongly linked to AL amyloidosis. To investigate this, we examined patient-derived κ-LCs in both glycosylated and unglycosylated forms. Mass spectrometry confirmed the presence of complex-type N-glycans. Biophysical analyses showed that glycosylation enhances structural compactness, stabilizes the native structure, and promotes cooperative unfolding. Glycosylated κ-LCs also exhibited reduced conformational dynamics. Functionally, N-glycosylation significantly improved LC secretion efficiency and extracellular stability. These findings suggest that N-glycosylation acts as a protective factor against amyloid formation and enhances LC accumulation outside the cell. Overall, our study highlights the multifaceted and context-dependent role of N-glycosylation in modulating κ-LC behavior, with important implications in AL pathogenesis.
2026-05-21 | A CDR1 aggregation hotspot controls unfolding kinetics and multimolecular aggregation in IGLV2 light chains.
Immunoglobulin light chains (LCs) exhibit diverse aggregation behaviours that depend sensitively on sequence composition and intermolecular interactions. Understanding how specific residues modulate aggregation kinetics remains a key challenge in elucidating the molecular basis of light-chain amyloidosis. Here, we investigate sequence-dependent aggregation using recombinant λ LCs derived from the IGLV2 gene family. Comparison of two closely related LCs differing by only 16 amino acids revealed striking differences in aggregation behaviour under thermal stress. Bioinformatic analysis identified an additional aggregation-prone segment in the CDR1 region of the aggregation-prone M10 variant, associated with residues Ser33 and Tyr34. Rational substitution of these residues (S33D/Y34S) markedly reduced aggregation while leaving the thermal transition temperature largely unchanged (∼53 °C). Differential scanning calorimetry revealed that the wild-type M10 LC unfolds with a significantly lower apparent activation energy (∼290 kJ/mol) compared with the non-aggregating H9 (∼605 kJ/mol) and the stabilised double mutant (∼560 kJ/mol), indicating reduced kinetic stability. Aggregation of unfolded species showed much weaker temperature dependence (Ea ≈ 10-70 kJ/mol) and exhibited strong concentration dependence consistent with a multimolecular association process. Additional experiments suggest that aromatic interactions involving Tyr34 contribute to the stabilisation of intermolecular assemblies. Together, these results establish a quantitative link between local sequence variation in the CDR1 region, kinetic stability of the LC fold, and aggregation propensity, highlighting how targeted mutations can modulate aggregation behaviour in immunoglobulin light chains.
2026-04-08 | Preventing Pathogenic Dimerization in a Misfolded Antibody Light Chain through the Design of an Inhibitory Peptide.
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. The disease correlates with the formation of insoluble aggregates mostly composed of patient-specific antibody light chains, whose hypervariable regions make each case unique and highlight the need for personalized therapeutics. In this study, we focused on a pathogenic homodimer we previously obtained from a patient-derived light chain. By analyzing the dynamics and the interface of this dimer, we identified a peptide with potential inhibitory activity. The peptide was then refined using a computational mutagenesis protocol that iteratively improved its sequence to maximize complementarity with the protein interface, taking into account shape, electrostatics, and hydropathy. The resulting optimized peptide is found to bind the monomer with a binding affinity comparable to that of the full pathogenic interface. These results suggest that the designed peptide could act as an effective antagonist of the pathogenic dimer, and demonstrate that our computational strategy could provide a general framework for designing patient-specific inhibitory peptides against aggregation-prone proteins.
2025-06-02 | The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies.
BackgroundAnti-CD38 directed therapies have emerged as targeted treatments for multiple myeloma (MM) and light chain (AL) amyloidosis. Intravenous immunoglobulin (IVIG) supplementation has been shown to reduce the risk of bacterial infections by 39% in patients with MM receiving anti-CD38 therapies, with a 72% reduction in grade 3-4 infections. However, there is currently no universal guidance on the optimal population in whom to initiate IVIG prophylaxis to prevent these infectious complications.MethodsThis study was a retrospective, single-centered chart review of eligible patients treated at Yale New Haven Health System (YNHHS) from 2016-2022. Eligible patients included adults with MM or AL amyloidosis treated with an anti-CD38 based regimen. The primary outcome was to compare the rate of pneumonia in patients who have received IVIG as compared to patients who have not. The secondary outcome was to identify the immunoglobulin G (IgG) level associated with an increased risk of pneumonia.ResultsRates of pneumonia were found to be higher within the population receiving IVIG as compared to those not receiving IVIG (29.55% vs. 15.41%, p = 0.05). There were no significant differences in the subgroup analyses including line of therapy, anti-CD38 agent, diagnosis, and IgG disease involvement. There was also no significant correlation demonstrated between baseline IgG level and the occurrence of pneumonia (β1 -0.0001, p = 0.37).ConclusionsIVIG supplementation in patients receiving anti-CD38 directed therapy did not significantly reduce the incidence of pneumonia. Given the lack of benefit with IVIG supplementation, careful consideration must be given prior to administration to limit unnecessary utilization.
cell therapies
2026-07-21 | Efficacy and Safety of BCMA-Targeted Therapies in Relapsed or Refractory AL Amyloidosis: A Descriptive Pooled Analysis.
B-cell maturation antigen (BCMA)-targeted therapies have emerged as promising treatment options for patients with relapsed/refractory immunoglobulin light-chain (AL) amyloidosis. However, comprehensive data on their efficacy and safety remain limited. We conducted a systematic descriptive pooled analysis of published studies reporting outcomes of BCMA-directed therapies including chimeric antigen receptor T-cell (CAR-T) therapies, bispecific antibodies (BsAbs), and antibody-drug conjugate (ADC). The analysis included 256 patients. CAR-T therapy was administered to 89 patients (35%), BsAbs to 82 patients (32%), and ADCs to 85 patients (33%). The pooled overall response rate (ORR) was 83%, with CAR-T demonstrating 92% ORR, BsAbs 89%, and ADCs 68%. Deep hematologic responses (≥VGPR) were achieved in approximately 70% of CAR-T and BsAb recipients and 64% of ADC recipients. Minimal residual disease negativity was documented in 75% of evaluable CAR-T patients and in 86% evaluable BsAb patients with reported data. Organ responses were observed in 30% of evaluable patients, with cardiac responses in 41%. Cytokine release syndrome occurred in 74% of CAR-T and 49% of BsAb patients, predominantly grade 1-2. Grade ≥3 CRS was rare (9% CAR-T, 1% BsAb). Ocular toxicity was the predominant adverse event in ADC recipients (84% any grade, 29% grade ≥3). Grade ≥3 infections occurred in 13% of CAR-T, 20% of BsAb, and 6% of ADC patients. BCMA-targeted therapies result in high response rates with manageable safety profiles in heavily pretreated AL amyloidosis patients, supporting continued investigation and clinical application of these approaches.
2026-06-23 | Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.
The role of autologous stem cell transplantation (ASCT) is central in AL amyloidosis and continues to be defined in the era of newer therapies. To evaluate contemporary patient selection, practice patterns, and outcomes, we conducted a retrospective, multicenter study across nine tertiary referral centers, including 1047 patients with AL amyloidosis who underwent ASCT between 2010 and 2020. Most patients (67.9%) received full-dose melphalan conditioning, and 66.5% received pre-ASCT induction therapy, predominantly proteasome inhibitor-based regimens. Day-100 all-cause mortality was 3.0%, representing a substantial improvement compared with historical cohorts. Post-ASCT hematological responses were satisfactory in 75.4% of patients. Among patients with paired assessments, ASCT deepened responses in 56.3% who had not achieved a complete response with induction therapy. With a median follow-up of 5.1 years, the median overall survival was 6.3 years. Independent predictors of inferior survival included age ≥60 years, bone marrow plasma cells ≥20%, pre-ASCT dFLC ≥40 mg/L, elevated cardiac biomarkers, lambda-restricted disease, reduced eGFR and reduced-dose conditioning. In this contemporary cohort, ASCT for AL amyloidosis demonstrated low early mortality, high rates of deep hematologic response, and durable survival in carefully selected patients. These findings support its role as an effective consolidative strategy, while its optimal positioning alongside emerging therapies requires further study.
2026-05-01 | A rare case of renal AHL amyloidosis with marked complement deposition: clinicopathologic and proteomic findings.
Amyloidosis comprises a heterogeneous group of diseases characterized by extracellular deposition of β-pleated-sheet fibrillar proteins that cause progressive organ dysfunction. Among immunoglobulin-related amyloidosis, combined heavy- and light-chain (AHL) amyloidosis is extremely rare, which accounts for approximately 7%. Several studies have demonstrated that complement components can be detected in renal amyloidosis. We report a rare case of renal AHL amyloidosis with marked complement deposition with clinicopathologic and proteomic insights. A 76-year-old woman with a five-year history of microscopic hematuria developed mild renal dysfunction (serum creatinine 1.05 mg/dL) and proteinuria (0.95 g/day). Physical and serologic evaluations showed no evidence of systemic amyloidosis or autoimmune disease. Serum and urine immunofixation detected an IgG-κ M-protein, and bone marrow findings were consistent with monoclonal gammopathy of undetermined significance. Kidney biopsy demonstrated Congo red-positive fibrillar deposits with IgG1, κ, and complement (C3/C1q) staining. Electron microscopy revealed non-branching fibrils measuring 8 to 12 nm in diameter. Because marked complement deposition was observed, fibrillary glomerulonephritis (FGN) was considered in the differential diagnosis. However, negative Dna J heat-shock protein family B member 9 immunostaining raised suspicion for amyloidosis. Mass spectrometry identified IgG1 heavy and κ light chains together with serum amyloid P and apolipoprotein E, confirming IgG1-κ-type AHL amyloidosis. This case illustrates a presentation of AHL amyloidosis with marked complement deposition. Recent study reveals that complement components can be detected in a subset of amyloidosis cases. These features can complicate the differential diagnosis from FGN and highlight the importance of an integrated diagnostic approach combining histopathology, immunostaining, and proteomic analysis. Furthermore, clone-directed therapy targeting the pathogenic plasma cell clone may represent a rational therapeutic strategy for monoclonal immunoglobulin-associated renal disease.
2026-02-05 | Improvement in Cardiac Magnetic Resonance Parameters in Patients With Cardiac Light-Chain Amyloidosis Receiving Anticlonal Cell Therapy.
We sought to evaluate the pattern of changes in cardiac magnetic resonance parameters among light-chain (AL) cardiac amyloidosis patients receiving anticlonal therapy. This study included 35 consecutive patients with AL cardiac amyloidosis (AL CA) from a single amyloidosis center, surviving at least 1 year after diagnosis and undergoing 3T CMR at diagnosis and at 12-months follow-up. Structural, functional parameters, native T1, T2, myocardial and spleen extracellular volume (ECV), and peak left atrial strain (PALS) were recorded. Hematologic response was assessed per current criteria. Mean age was 64.1 years, 57% males and per Mayo staging system 10% were stage I, 32% stage II, and 58% stage III. During follow-up, 54.3% achieved complete hematologic response (CR), 34.3% very good partial response, and 11.4% partial response. Significant changes at 12-month landmark included a reduction in native T1 (1420 ms vs. 1393 ms, P = .001), ECV (46% vs. 43%, P = .004), left ventricular maximum wall thickness (15 mm vs. 13 mm, P = .02), and an increase in stroke volume (76 mL vs. 85 mL, P = .016). Patients with complete hematologic or cardiac response demonstrated improvements in T1 native and ECV. In a subset of n = 12 patients with a repeated follow-up CMR study at a median of 31.2 ± 5.04 months after treatment initiation, a trend towards further reduction in T1 and ECV was noted. In AL-CA patients treated with anticlonal therapy, significant improvement in CMR parameters, correlate with hematologic and organ response and suggest potential cardiac amyloid regression and functional improvement.
2025-12-08 | Up-to-date review on heart transplantation and other advanced heart failure therapies in cardiac amyloidosis patients.
Cardiac amyloidosis (CA) can result in a restrictive cardiomyopathy, and heart transplantation (HT) remains the gold standard treatment for patients with end-stage heart failure secondary to amyloid cardiomyopathy. Although HT was historically contraindicated due to inferior outcomes, survival following HT in patients with CA has significantly improved over recent decades; and outcomes are now similar to those of patients undergoing HT for non-amyloid indications. This improvement has been driven largely by advances in screening for appropriate patient selection and improvement in therapeutic strategies for both immunoglobulin light-chain (AL) and transthyretin (ATTR) amyloidosis. Future directions in HT for CA will hinge on continued optimization of patient selection and refining post-transplant management of extracardiac manifestations.
antibodies
2026-09-13 | 294th ENMC international workshop: Diagnosis and management of paraproteinemic myopathies focusing on sporadic late-onset nemaline myopathy (SLONM) and light-chain (AL) amyloid myopathy. 27th -29th March 2026, Hoofddorp, The Netherlands.
Paraproteinemic myopathies are rare but potentially treatable disorders caused by pathogenic monoclonal proteins, yet diagnosis is often delayed because of nonspecific clinical manifestations and the lack of standardized diagnostic approaches. The 294th ENMC International Workshop convened 21 experts from 12 countries and two patient representatives to establish international consensus on their diagnosis and management. The workshop reviewed current evidence on sporadic late-onset nemaline myopathy (SLONM), light-chain (AL) amyloid myopathy, vacuolar myopathy with monoclonal gammopathy and stiffness (VAMMGAS), and scleromyxedema-associated myopathy. Clinical red flags include age at symptom onset ≥40 years, subacute proximal and/or axial weakness, normal or mildly elevated creatine kinase levels (except in VAMMGAS), dysphagia, weight loss, systemic manifestations, and poor response to conventional immunotherapy. Consensus diagnostic criteria for SLONM and a diagnostic algorithm for paraproteinemic myopathies were established. Routine Congo red staining of muscle biopsies, particularly in patients with monoclonal protein, was recommended. The workshop endorsed replacing SLONM-MGUS with SLONM-MP to reflect the pathogenic role of the monoclonal protein and recommended plasma cell-directed therapy as the cornerstone of treatment for SLONM-MP and AL amyloid myopathy. These recommendations provide the first international consensus framework for the diagnosis and management of paraproteinemic myopathies and establish priorities for future collaborative research.
2026-08-28 | 9-Year Serial CMR Monitoring of Cardiac AL Amyloidosis Regression After Teclistamab.
Cardiac amyloid light-chain (AL) amyloidosis carries a poor prognosis and is considered largely irreversible once symptomatic. Long-term serial cardiovascular magnetic resonance (CMR) data following B-cell maturation antigen-directed therapy are lacking. A 64-year-old man with biopsy-proven cardiac AL amyloidosis achieved sustained hematologic complete response after teclistamab following failure of 4 prior lines including daratumumab. Eleven CMR examinations over 9 years documented a biphasic trajectory: progressive infiltration through 2020 (left ventricular mass 186 g, wall thickness 18 mm, global longitudinal strain -4.8%), followed by sustained structural and functional regression through 2025 (left ventricular mass 127 g, wall thickness 13 mm, global longitudinal strain -13.7%). This represents the longest serial CMR follow-up in cardiac AL amyloidosis reported to date, demonstrating that cine-derived parameters reliably track cardiac regression in real-world conditions. Native T1 normalized while extracellular volume fraction (ECV) paradoxically increased, suggesting persistent fibril burden beyond hematologic clearance. Serial CMR with cine-derived parameters provides robust longitudinal monitoring of cardiac AL amyloidosis regression following novel plasma cell-directed therapy, even without systematic contrast enhancement.
2026-08-10 | IgM Pleural Amyloidosis Diagnosed by Pleural Effusion Cell Block: A Case Report.
Immunoglobulin light chain (AL) amyloidosis is characterized by the systemic deposition of light-chain-derived amyloids. Immunoglobulin M (IgM)-associated AL amyloidosis is extremely rare and clinically distinct. A 70-year-old man presented with dyspnea, bilateral pleural effusion, and mediastinal lymphadenopathy on computed tomography (CT). Amyloid was detected in a pleural effusion cell block and confirmed via an axillary lymph node biopsy. Serum studies and bone marrow findings supported IgM-λ AL amyloidosis associated with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. First-line therapy failed, but second-line therapy reduced pleural effusion, avoiding thoracentesis for one year. A pleural effusion cell block analysis enabled rapid diagnosis with minimally invasive exploration.
2026-07-20 | Histopathological improvement in kidney AL amyloid deposits following daratumumab-based chemotherapy and autologous peripheral blood stem cell transplantation: a case report.
AL amyloidosis is characterized by extracellular deposition of immunoglobulin light-chain fibrils, frequently leading to kidney involvement and progressive organ dysfunction. We report a case of kidney AL amyloidosis secondary to multiple myeloma in which daratumumab-based chemotherapy combined with autologous peripheral blood stem cell transplantation resulted in marked improvement, as confirmed by sequential kidney biopsy. The initial biopsy revealed vascular-dominant amyloid deposition, whereas the second biopsy obtained 2 years later demonstrated a marked reduction in amyloid burden, particularly within the vascular compartments. This histopathological improvement corresponded with hematologic remission and stabilization of kidney function. The observed reduction in tissue amyloid deposits was presumed to result from suppression of amyloidogenic light chains, leading to inhibition of new fibril formation and subsequent tissue remodeling. Our findings provide direct pathological evidence that daratumumab-based combination therapy, through immune-mediated plasma cell depletion, may indirectly promote the regression of amyloid deposits and contribute to functional recovery.
2026-07-09 | Systemic light chain and transthyretin amyloidosis-treatment advancements and future directions.
Once rapidly fatal, neglected, and orphan diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. Basic scientific discoveries regarding the molecular mechanisms of transthyretin misfolding and aggregation have driven the development of drugs for the treatment of transthyretin (ATTR) amyloidosis, with six novel therapies approved since 2018. The combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone was approved for the treatment of light chain (AL) amyloidosis in 2021. Since then, highly effective immunotherapies, such as bispecific T-cell engagers, have been tested in clinical trials in patients with relapsed AL amyloidosis, with unprecedented efficacy. Thus, suspicion of systemic amyloidosis should be raised early in individuals with a suggestive clinical presentation, followed by rapid tissue diagnosis, with appropriate protein typing and prompt commencement of active therapy. These rapid and exciting therapeutic advancements set the stage for this Review on the epidemiology, pathophysiology, and diagnosis of systemic amyloidosis. Through the lens of the molecular mechanisms underlying amyloidosis pathogenesis, we will focus on approved and investigational therapies. We also discuss future directions and challenges concerning a cure for patients with AL or ATTR amyloidosis.
other
2025-09-27 | What Cardiologists Should Know About Amyloidosis.
Background: Cardiac amyloidosis (CA) is an increasingly recognized but historically underdiagnosed cause of restrictive cardiomyopathy and heart failure with preserved ejection fraction (HFpEF). It results from the extracellular deposition of misfolded protein fibrils, most commonly transthyretin (ATTR) or immunoglobulin light chains (AL), leading to progressive myocardial dysfunction and multi-organ involvement. Objective: This review provides a comprehensive, cardiology-centered overview of cardiac amyloidosis, with an emphasis on early recognition, diagnostic strategies, subtype differentiation, and the evolving therapies. Content: We summarize the epidemiology, pathophysiology, and clinical manifestations of both ATTR and AL subtypes. Key diagnostic tools, including echocardiography, cardiac magnetic resonance imaging, bone scintigraphy, monoclonal protein screening, and endomyocardial biopsy, are reviewed in the context of a stepwise diagnostic approach. Special attention is given to clinical presentation, electrocardiographic and imaging "red flags," and to differentiating CA from mimickers such as hypertrophic cardiomyopathy, hypertension-induced left ventricular hypertrophy, and aortic stenosis. Staging systems are detailed, highlighting the prognostic role of cardiac biomarkers. Therapeutic strategies are explored, including subtype-specific regimens (e.g., daratumumab-based therapy for AL; tafamidis and gene silencers for ATTR), the judicious use of conventional heart failure medications, and emerging therapies such as CRISPR-based gene editing. Conclusions: Timely recognition and accurate diagnosis of cardiac amyloidosis are critical to improving outcomes. As diagnostic tools and disease-modifying therapies evolve rapidly, cardiologists must remain at the forefront of multidisciplinary care. A structured biomarker- and imaging-guided approach can enhance diagnostic yield, inform prognosis, and optimize patient-specific management.
2025-09-26 | Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy.
Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) is a rare, multisystem, progressive, debilitating, and fatal disease characterized by tissue deposition of misfolded transthyretin (TTR) in peripheral nerves. Nexiguran ziclumeran (nex-z) is an investigational in vivo therapy based on CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease) that is designed to reduce serum TTR levels through selective inactivation of TTR in the liver. In this phase 1, open-label study, we administered one infusion of nex-z to patients with ATTRv-PN. Primary objectives included assessment of the safety and pharmacodynamics of nex-z. Secondary end points included changes in the familial amyloid polyneuropathy stage, polyneuropathy disability score, serum neurofilament light chain (NfL) level, modified body-mass index (modified BMI, defined as the conventional BMI [weight in kilograms divided by square of height in meters] multiplied by the albumin level in grams per liter), and modified Neuropathy Impairment Score+7 (mNIS+7; range, 0 to 304, with higher scores indicating more impairment). A total of 36 patients received nex-z; the mean follow-up was 27 months. The mean percent change from baseline in the serum TTR level was -90% at day 28, which was sustained through month 24 (-92%). Treatment-related adverse events included transient infusion-related reactions (in 21 patients), decreased thyroxine level without hypothyroidism or elevated thyrotropin level (in 8), and headache (in 4). One participant died from cardiac amyloidosis, and one withdrew owing to progressive decline in motor function. Serious adverse events were reported in 11 patients. At month 24, the familial amyloid polyneuropathy stage and polyneuropathy disability score remained stable in 29 and 27 patients, respectively; improved in 2 and 5, respectively; and worsened in 2 and 2, respectively. The mean change in the serum NfL level was -9.0 pg per milliliter, and the change in the modified BMI was 24.7. The mean change from baseline in the mNIS+7 was -8.5. A single administration of nex-z in patients with ATTRv-PN was associated with rapid, deep, and durable reductions in serum TTR levels. The results support further investigation of nex-z to treat ATTRv-PN. (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
2025-05-28 | Cardiac Amyloidosis: A Narrative Review of Diagnostic Advances and Emerging Therapies.
Background/Objectives: Cardiac amyloidosis (CA) is an underdiagnosed and potentially life-threatening infiltrative cardiomyopathy characterized by the extracellular deposition of misfolded amyloid fibrils in cardiac tissue. It is most commonly associated with light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis, either hereditary or wild-type. The disease often presents with non-specific symptoms, leading to delayed diagnosis and treatment. This study aims to provide a comprehensive overview of the pathophysiology, diagnostic strategies, and current therapeutic approaches for cardiac amyloidosis, with a focus on improving early detection and clinical outcomes. Methods: A narrative review was conducted using databases such as PubMed and Scopus, covering the period from September 2016 to March 2025. Keywords such as "cardiac amyloidosis", "cardiac amyloidosis from transthyretin", "cardiomyopathy", "transthyretin", "immunoglobulin light-chain amyloidosis", and "familial amyloidosis" were used. Relevant clinical trials and guideline-based management recommendations were also included. Results: This review highlights that non-invasive imaging modalities and serum biomarker analyses are key to reducing diagnostic delays. New therapeutic developments, including gene-editing technologies and RNA-based therapies, show promise in early trials. Multidisciplinary management and increased awareness are crucial for timely diagnosis and treatment optimization. Conclusions: The early recognition of cardiac amyloidosis remains a major clinical challenge. Advances in non-invasive diagnostics and emerging disease-modifying therapies are transforming the prognosis of affected patients. Continued research and heightened clinical suspicion are essential to improve outcomes in this complex and heterogeneous disease.
2025-01-17 | New therapies to treat cardiac amyloidosis.
Review advancements in therapies for transthyretin (ATTR-CM) and immunoglobulin light chain (AL-CM) cardiac amyloidosis. In ATTR-CM, tafamidis remains the cornerstone therapy, with Food and Drug Administration (FDA) approval for over 5 years. Acoramidis, another transthyretin stabilizer, has very recently been FDA-approved following positive results in the ATTRibute-CM trial. Vutrisiran, a transthyretin gene silencer, demonstrated efficacy in the HELIOS-B trial and awaits FDA review. Eplontersen's CARDIO-TTRansform trial, the largest ATTR-CM study to date, is expected to report by late 2025. Innovative approaches such as NTLA-2001 (a CRISPR-Cas9 therapy) and fibril depleters like ALXN2220 and coramitug are advancing in clinical trials. In AL-CM, daratumumab, cyclophosphamide, bortezomib, and dexamethasone (Dara-CyBorD) has established itself as the standard of care. Novel antiplasma cell therapies include CAR-T cells and bispecific antibodies (teclistimab) and fibril depleters. Birtamimab improved survival in advanced AL-CM during the VITAL trial and is under investigation in AFFIRM-AL. Anselamimab is in phase III CARES trials, whereas AT-02 undergoes early-phase testing for ATTR-CM and AL-CM. The therapeutic landscape for ATTR-CM and AL-CM is rapidly evolving, driven by novel therapies targeting diverse mechanisms. Ongoing clinical trials promise to further refine the standard of care and improve outcomes for patients with cardiac amyloidosis.
2024-08-19 | Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment.
Cardiac amyloidosis (CA) is a condition characterized by misfolding and extracellular deposition of proteins, leading to organ dysfunction. While numerous forms of CA exist, two subtypes dominate clinical prevalence: Transthyretin amyloid (ATTR) and immunoglobulin light chain amyloid. The current scientific landscape reflects the urgency to advance therapeutic interventions with over 100 ongoing clinical trials. Heart failure treatment is affected by CA phenotype with poor tolerance of otherwise frequently used medications. Treating comorbidities including atrial fibrillation and valvular disease remains a challenge in CA, driven by technical difficulties and uncertain outcomes. Tafamidis is the first ATTR-stabilizer approved with a rapidly growing rate of clinical use. In parallel, various new therapeutic classes are in late-stage clinical trials including silencers, antibodies and genetic therapy. Managing CA is a critical challenge for future heart failure care. This review delineates the current standard-of-care and scientific landscape of CA therapy.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
26 orphan drug designations for AL amyloidosis, including 2 approved therapies.
26 orphan drug designations for AL amyloidosis, including 2 approved therapies.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
zamubafusp alfa | proteins | FDA | Attralus, Inc. | |
revlucabtagene autoleucel | cell therapies | FDA | Nexcella, Inc. | |
Humanised IgG1 monoclonal antibody against misfolded immunoglobulin G, fused with pan-amyloid-reactive peptide p5R | antibodies | EMA | Raremoon Consulting Esp S.L. | |
Autologous CD3-positive T-cells expressing a chimeric antigen receptor against B cell maturation agent | cell therapies | EMA | — | Raremoon Consulting Esp S.L. |
Bortezomib | small molecules | EMA | Accord Healthcare S.L. | |
Autologous T cells expressing anti-B cell maturation agent chimeric antigen receptor | cell therapies | FDA | Nexcella, Inc. | |
Iodine (I124) evuzamitide | small molecules | FDA | Attralus, Inc. | |
Iodine (124I) evuzamitide | proteins | EMA | Raremoon Consulting Esp S.L. | |
daratumumab and hyaluronidase-fihj [Darzalex Faspro] | antibodies | FDA | Approved | Janssen Research & Development, LLC |
Florbetaben (18F) | small molecules | EMA | Lantheus Germany GmbH | |
florbetaben F18 | small molecules | FDA | Lantheus Biosciences Ltd. | |
Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4 | antibodies | EMA | Alexion Europe S.A.S. | |
Daratumumab [Darzalex] | antibodies | EMA | Approved | Janssen Cilag International |
daratumumab | antibodies | FDA | Janssen Research & Development, LLC | |
carboxy pyrrolidine hexanoyl pyrrolidine carboxylate | small molecules | FDA | Glaxo Group Limited, England d/b/a GlaxoSmithKline | |
recombinant monoclonal antibody to human serum amyloid P component | antibodies | FDA | Glaxo Group Limited, England d/b/a GlaxoSmithKline | |
N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide | small molecules | FDA | — | ProtaMed, Inc. |
Miridesap [GSK2315698] | small molecules | EMA | Glaxosmithkline Trading Services Limited | |
Dezamizumab [GSK2398852] | antibodies | EMA | Glaxosmithkline Trading Services Limited | |
Revusiran | RNAs | EMA | Alnylam UK Limited | |
Humanised IgG1 kappa antibody against serum amyloid A and AL amyloid | antibodies | EMA | Prothena Biosciences Limited | |
Ixazomib citrate [Ninlaro] | small molecules | EMA | Takeda Pharma A/S | |
2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate) | small molecules | FDA | Millennium Pharmaceuticals, Inc. | |
monoclonal antibody 11-1F4 | antibodies | FDA | Caelum Biosciences, Inc. | |
Tafamidis meglumine [Vyndaqel] | small molecules | EMA | Pfizer Europe MA EEIG | |
Iodine (123I) serum amyloid P component [Amysap] | proteins | EMA | — | [INACTIVE] Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.